Sep 9, 2008|
Of oil prices and Japanese pharma...
Also read - Mortgage giants get 'capital' punishment
Indian stock market closed with strong gains yesterday as the NSG waiver and the US government's bailout of Freddie and Fannie converged to buoy sentiments among the investors. The NSG waiver is a huge positive for the Indian economy and will attract much needed investments in the country's deficient power sector. Furthermore, the US government's takeover of the two US mortgage giants fired up the Asian and European indices. According to Bloomberg, Treasury Secretary Henry Paulson said that the government will provide short-term funding to the two mortgage-finance companies and purchase debt backed by home loans.
In the meanwhile, oil prices continued to dance to the tunes of the hurricane season. After Gustav, it is hurricane Ike, which has delayed the resumption of crude production in the Gulf of Mexico. This led crude prices to rise by US$ 2 a barrel.
Gulf is in a dilemma
While markets across the world are breathing a sigh of relief at the fall in crude prices, the OPEC is not necessarily gung-ho about these developments. Oil prices have fallen considerably after the high of US$ 147 a barrel reached in July and are expected to fall below the psychological US$ 100 barrel for the first time since March. Fall in consumption is one of the major factors contributing to this decline. An economic slowdown is weighing heavy on the Americans, who are cutting back on their fuel consumption and given that US is the largest consumer of oil, a slowdown in this country is certainly contributing to the meltdown in crude prices.
Oil producers are in a quandary. Some of them do not want prices to drop below US$ 100 a barrel, as it would greatly undermine their revenues. If they cut production to support the high prices, they stand the risk of being perceived as profiteers. At the same time, leaving production unchanged may trigger the decline in prices at a time when oil demand is slowing. The International Herald Tribune states, "Venezuela and Iran, the leading price hawks within the group, said they did not want oil to fall below US$ 100 a barrel, a price Iran's oil minister recently said was a minimum level. Both countries signaled that members of the OPEC needed to reduce their output to prevent prices from dropping further. Other OPEC members, like Algeria or Kuwait, fear that high-energy costs could jeopardize their exports as the global economy slows down and consumers reduce their consumption. Saudi Arabia, the world's top oil exporter, has not said what would be a fair price, although King Abdullah has said that US$ 100 was too high".
Japan making strides in pharma
The Japanese pharmaceutical industry is witnessing a flurry of activity especially in the merger space. After acquisitions made by Eisai and Daiichi Sankyo, the latest entrant in the M&A club is Shionogi, a strong player in the antibiotics space, who has acquired the US based company Sciele Pharma for US$ 1.1 bn. This is the fourth big overseas deal in nine months by Japanese drug makers. Infact, already in the year so far, overseas acquisitions from Japan have totaled US$ 42 bn, which is nearly double the figure for all of 2007. Japan, in recent times, is also being afflicted by the challenges facing other developed nations, namely rise in the aged population, increasing healthcare costs and pressure on the government to reduce these costs. Given the fact that the R&D pipelines of major global innovators including the Japanese companies are drying up, many of them are looking to augment their product portfolios by either acquiring small innovators or generic companies.
In recent times, the Japanese government has been laying increased stress on reducing the healthcare burden and has started introducing some healthcare reforms, which have been pro-generic. This is a huge step for a nation, where generic penetration was very low, despite being the second largest pharma market in the world, as generics were perceived to be 'inferior'. Indian companies have also been making some progress in the Japanese pharma market. While the Ranbaxy-Daiichi combine will strengthen the former's presence in the Japanese market, players like Lupin and Cadila have also identified Japan as in important market to bolster revenues from generics. Also read - The Japanese market is waiting to be tapped...
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
Aug 16, 2017
And what it has in common with beating the stock market too.
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 14, 2017
Last week's correction is making a number of Super Investor stocks look a lot more attractive...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407